RE: Today’s rise24 Nov 2025 11:36
If you read the RNS's it might be help you to understand a lot more about Sheild,
London, UK, 14 November 2025 Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, today announced that its partner, MEDLEAP Pharma, a subsidiary of Vital KSK Holdings Inc. has initiated a Phase II clinical trial for ACCRUFER® (ferric maltol), a new drug candidate for Pulmonary Arterial Hypertension (PAH), for patients in Japan. This trial is an exploratory study to support a Phase III trial and follows confirmation by the Pharmaceuticals and Medical Devices Agency (PMDA) of the development plan for the drug as a PAH treatment in Japan, based on previous clinical results in Europe, UK and USA.